Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $46.1250.

Several research analysts recently commented on CLDX shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $62.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, September 17th. HC Wainwright lowered their price objective on Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating for the company in a research note on Wednesday, August 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Saturday, September 27th. Wells Fargo & Company lowered their price target on Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a research report on Wednesday, August 20th. Finally, Citigroup dropped their price objective on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research note on Wednesday, August 20th.

Institutional Trading of Celldex Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB boosted its position in shares of Celldex Therapeutics by 2.4% during the second quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company’s stock valued at $440,000 after buying an additional 500 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after acquiring an additional 680 shares during the period. AlphaQuest LLC grew its position in Celldex Therapeutics by 7.0% in the 2nd quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 844 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Celldex Therapeutics by 171.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 881 shares during the last quarter.

Celldex Therapeutics Stock Performance

CLDX stock opened at $26.41 on Monday. The firm has a fifty day moving average price of $23.55 and a 200 day moving average price of $21.24. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $31.66. The firm has a market cap of $1.75 billion, a PE ratio of -8.77 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The business had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.13 million. On average, equities analysts predict that Celldex Therapeutics will post -2.48 EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.